Argitalpenak (221) Ikertzaileren baten partaidetza izan duten argitalpenak

filter_list

2025

  1. ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker: CHRONIC LYMPHOCYTIC LEUKEMIA

    Leukemia

  2. Acute promyelocytic leukemia: long-term outcomes from the HARMONY project

    Blood, Vol. 145, Núm. 2, pp. 234-243

  3. Comparability of external and internal control patients for the prospective randomized HOVON-103 trial in older AML patients

    British Journal of Haematology

  4. Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL

    HemaSphere, Vol. 9, Núm. 1

  5. Examining the Effects of the RUNX1 p.Leu43Ser Variant on FPD/AML Phenotypes Using a CRISPR/Cas9-Generated Knock-In Murine Model

    Biomolecules, Vol. 15, Núm. 5

  6. NOTCH1 signaling is dysregulated by loss of the deubiquitinase USP28 with del(11q), uncovering USP28 inhibition as novel therapeutic target in CLL

    Leukemia

  7. Optimizing Patient Registries for Regulatory Decision Making - Key Learnings From an HMA/EMA Multistakeholder Workshop

    Clinical Pharmacology and Therapeutics

  8. Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance

    Haematologica, Vol. 110, Núm. 5, pp. 1126-1140

  9. Regional patterns of early-onset colorectal cancer from the GEOCODE (Global Early-Onset COlorectal Cancer DatabasE)-European consortium: Retrospective cohort study

    BJS Open, Vol. 9, Núm. 2

  10. SAMHD1 dysfunction impairs DNA damage response and increases sensitivity to PARP inhibition in chronic lymphocytic leukemia

    Scientific Reports, Vol. 15, Núm. 1

  11. Sex Differences in Gut Microbiota and Their Relation to Arterial Stiffness (MIVAS Study)

    Nutrients , Vol. 17, Núm. 1

  12. Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trial

    The Lancet Haematology, Vol. 12, Núm. 7, pp. e529-e541